Stephen Basso
Director Financiero/CFO en INNOVIVA, INC. .
Fortuna: 181 319 $ al 30/04/2024
Cargos activos de Stephen Basso
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INNOVIVA, INC. | Director Financiero/CFO | 21/08/2023 | - |
Historial de carrera de Stephen Basso
Antiguos cargos conocidos de Stephen Basso.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INOZYME PHARMA, INC. | Comptroller/Controller/Auditor | 01/10/2017 | 14/05/2021 |
| Director Financiero/CFO | 01/10/2017 | 14/05/2021 | |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2009 | 01/05/2017 |
Cybrexa, Inc.
 Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director de Operaciones | - | - |
| Director Financiero/CFO | - | - |
Formación de Stephen Basso.
| Providence College | Undergraduate Degree |
| Boston College | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Director of Finance/CFO | 3 |
| Comptroller/Controller/Auditor | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| INNOVIVA, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Basso
- Experiencia
